p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.
Adams
J L
JL
Smith Kline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, USA.
Badger
A M
AM
Kumar
S
S
Lee
J C
JC
D000595:Amino Acid Sequence; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000502:physiology; D001168:Arthritis / Q000188:drug therapy / Q000201:enzymology; D001842:Bone and Bones / Q000201:enzymology; D002356:Cartilage / Q000201:enzymology; D017321:Clinical Trials, Phase I as Topic; D065607:Cytochrome P-450 Enzyme Inhibitors; D016207:Cytokines / Q000037:antagonists & inhibitors*; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008168:Lung / Q000201:enzymology; D008171:Lung Diseases / Q000188:drug therapy / Q000201:enzymology; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics; D023421:Models, Animal; D008969:Molecular Sequence Data; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000201:enzymology; D009389:Neovascularization, Pathologic; D011565:Psoriasis / Q000201:enzymology; D011725:Pyridines / Q000627:therapeutic use; D016415:Sequence Alignment; D012772:Shock, Septic / Q000188:drug therapy / Q000201:enzymology; D020521:Stroke / Q000188:drug therapy / Q000201:enzymology; D014777:Virus Diseases / Q000188:drug therapy / Q000201:enzymology; D048051:p38 Mitogen-Activated Protein Kinases
D000893:Anti-Inflammatory Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D016207:Cytokines; D004791:Enzyme Inhibitors; D007093:Imidazoles; D011725:Pyridines; C403289:SB 242235; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases